James W. Smithy

1.5k total citations
41 papers, 691 citations indexed

About

James W. Smithy is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James W. Smithy has authored 41 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 12 papers in Immunology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in James W. Smithy's work include Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (10 papers). James W. Smithy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (27 papers), CAR-T cell therapy research (15 papers) and Immunotherapy and Immune Responses (10 papers). James W. Smithy collaborates with scholars based in United States, Greece and United Kingdom. James W. Smithy's co-authors include David L. Rimm, Maria Toki, Harriet M. Kluger, Pok Fai Wong, Konstantinos N. Syrigos, Wei Wei, Daniel Zelterman, Jamaal Rehman, Patricia Gaule and Delphine Cougot and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

James W. Smithy

37 papers receiving 685 citations

Peers

James W. Smithy

ONCOL

IMMUN

PRM

Giulia Mazzaschi Italy

Fareeda Hosein United States

E. Jensen United States

Mark Voskoboynik Australia

Keyi Jia China

Ashley Kowalewski United States

Yuzi Zhang China

Christian Britschgi Switzerland

Esther Holgado Spain

Wilbur Pan United States

Giulia Mazzaschi Italy

James W. Smithy

444 ×0.8

ONCOL

166 ×0.6

IMMUN

254 ×1.2

PRM

130 ×0.9

96 ×0.9

Citations per year, relative to James W. Smithy James W. Smithy (= 1×) peers Giulia Mazzaschi

Countries citing papers authored by James W. Smithy

Since Specialization

Citations

This map shows the geographic impact of James W. Smithy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James W. Smithy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James W. Smithy more than expected).

Fields of papers citing papers by James W. Smithy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James W. Smithy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James W. Smithy. The network helps show where James W. Smithy may publish in the future.

Co-authorship network of co-authors of James W. Smithy

This figure shows the co-authorship network connecting the top 25 collaborators of James W. Smithy. A scholar is included among the top collaborators of James W. Smithy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James W. Smithy. James W. Smithy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smithy, James W., Adam J. Schoenfeld, & Allison Betof Warner. (2025). The Clinical TIL Experience in Melanoma: Past, Present, Future. Transplantation and Cellular Therapy. 31(3). S626–S634. 1 indexed citations

Smithy, James W., et al.. (2025). Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis. Nature Communications. 16(1). 6619–6619. 1 indexed citations

Smithy, James W., Andrea P. Moy, Colleen Maher, et al.. (2025). Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma. Cell Reports. 44(4). 115554–115554. 1 indexed citations

Smithy, James W., Ronak Shah, Matthew Adamow, et al.. (2024). Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study. Clinical Cancer Research. 30(16). 3407–3415. 4 indexed citations

Warner, Allison Betof, James W. Smithy, Nathan Hasson, et al.. (2024). 1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma. Annals of Oncology. 35. S730–S731. 2 indexed citations

Powles, Thomas, Aakanksha Bhatia, Barbara Burtness, et al.. (2024). 690TiP HERTHENA-PanTumor01: A global phase II trial of HER3-DXd in metastatic solid tumors. Annals of Oncology. 35. S534–S535. 2 indexed citations

Kemel, Yelena, James W. Smithy, Diana Mandelker, et al.. (2024). Germline pathogenic variants in a large convenience cohort of multiple melanoma subtypes.. Journal of Clinical Oncology. 42(16_suppl). 9595–9595. 1 indexed citations

Warner, Allison Betof, James W. Smithy, Michael A. Postow, et al.. (2024). A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases.. Journal of Clinical Oncology. 42(16_suppl). TPS9603–TPS9603. 1 indexed citations

Bhatia, Aarti, Hidetoshi Hayashi, Takahiro Kogawa, et al.. (2024). HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS3164–TPS3164. 1 indexed citations

10.

Smithy, James W., Parisa Momtaz, Alexander N. Shoushtari, et al.. (2024). A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.. Journal of Clinical Oncology. 42(16_suppl). TPS9605–TPS9605.

11.

Smithy, James W., Colleen Maher, Alexander N. Shoushtari, et al.. (2023). Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).. Journal of Clinical Oncology. 41(16_suppl). 9517–9517.

12.

Vanguri, R., James W. Smithy, Yanyun Li, et al.. (2023). Integration of peripheral blood‐ and tissue‐based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. The Journal of Pathology. 261(3). 349–360. 6 indexed citations

13.

Smithy, James W., Yanyun Li, Andrea P. Moy, et al.. (2023). 1303 Spatial topic modeling of tumor microenvironment with multiplexed imaging. SHILAP Revista de lepidopterología. A1448–A1448. 1 indexed citations

14.

Loo, Kimberly, James W. Smithy, Michael A. Postow, & Allison Betof Warner. (2022). Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. Frontiers in Immunology. 12. 810388–810388. 13 indexed citations

15.

Smithy, James W., David M. Faleck, & Michael A. Postow. (2021). Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events. Clinical Cancer Research. 28(7). 1250–1257. 20 indexed citations

16.

Toki, Maria, Christopher R. B. Merritt, Pok Fai Wong, et al.. (2019). High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling. Clinical Cancer Research. 25(18). 5503–5512. 111 indexed citations

17.

Wong, Pok Fai, Wei Wei, James W. Smithy, et al.. (2019). Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. Clinical Cancer Research. 25(8). 2442–2449. 103 indexed citations

18.

Gupta, Swati, Yvonne G. Y. Chan, Edwin W. Lai, et al.. (2019). Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma. Journal for ImmunoTherapy of Cancer. 7(1). 254–254. 13 indexed citations

19.

Toki, Maria, Nikita Mani, James W. Smithy, et al.. (2018). Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. Journal of Thoracic Oncology. 13(12). 1884–1896. 82 indexed citations

20.

Toki, Maria, Nikita Mani, James W. Smithy, et al.. (2017). Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations.. Journal of Clinical Oncology. 35(15_suppl). 9076–9076. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact